Misoprostol treatment exacerbates abdominal discomfort in patients with non-ulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo-controlled, multicentre study.
One hundred and thirty-seven consecutive outpatients with non-ulcer dyspepsia (NUD) and erosive prepyloric changes (EPC) were randomly allocated to double-blind treatment with 400-micrograms misoprostol tablets twice daily or placebo for 4 weeks. Misoprostol had a significant worsening effect on epigastric pain, nausea, meteorism, lower abdominal pain, and diarrhoea, as compared with placebo. The fact that symptoms in patients with NUD and EPC were exacerbated by an antisecretory dose of misoprostol indicates that the symptoms are largely unrelated to gastric acid.
Hausken
T
T
Medical Dept., Haukeland Hospital, Bergen, Norway.
Stene-Larsen
G
G
Lange
O
O
Aronsen
O
O
Nerdrum
T
T
Hegbom
F
F
Schulz
T
T
Berstad
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004311:Double-Blind Method; D004415:Dyspepsia / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016595:Misoprostol; D011708:Pylorus / Q000187:drug effects / Q000503:physiopathology
D000897:Anti-Ulcer Agents; D016595:Misoprostol; D000527:Alprostadil